 Dilated cardiomyopathy, DCM, is a genetic disease caused by mutations in certain genes that lead to abnormalities in the structure or function of the heart. These mutations can be corrected using CSPR technology, but there are several challenges associated with this approach. In order to overcome these challenges, researchers used a combination of CSPR base editors and AAV-MYO, a virus vector designed specifically for delivering CSPR components into the heart. This combination successfully restored the normal function of the heart in two different mouse models of DCM. The results suggest that CSPR technology could be used to treat DCM in humans. This article was offered by Marcus Grosh, Laura Schraft, Adrian Chan, and others.